FIELD: medicine, pharmaceutics.
SUBSTANCE: there is described new macrocyclic compound of general formula 1-c:
and its pharmaceutically acceptable acid or base addition salts or its stereoisomers (the radical values are presented in the patent claim).
EFFECT: producing the compounds which are hepatitis type C virus inhibitors and can find application in medicine.
9 cl, 1 tbl, 95 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW DIAMIDES PYRIMIDIN-4,6 OF DICARBOXYLIC ACID FOR SELECTIVE INHIBITION OF COLLAGENASES | 2003 |
|
RU2344129C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | 2006 |
|
RU2441870C2 |
| HEPATITIS C VIRUS MACROCYCLIC INHIBITORS | 2006 |
|
RU2486189C2 |
| TARTRATE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446160C2 |
| ANTIVIRAL COMPOUNDS | 2009 |
|
RU2505539C2 |
| MACROCYCLIC PHENYLCARBAMATES INHIBITING HCV | 2008 |
|
RU2490261C2 |
| ALLOSTERIC MODULATORS OF METABOLIC GLUTAMATE RECEPTORS | 2004 |
|
RU2360902C2 |
| SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | 2012 |
|
RU2621695C2 |
| ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
Authors
Dates
2011-05-27—Published
2006-07-28—Filed